Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer

por Hou, Xinlei, Shi, Xueliang, Luo, Jie
Publicado 2022

Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Deve...

por He, Junming, Zhao, Jun, Quan, Yuhe, Hou, Xinlei, Yang, Meixiang, Dong, Zhongjun
Publicado 2021

Polo-like kinase (PLK) 5, a new member of the PLK family, serves as a biomarker to indicate anabatic tumor burden and poor prognosis for resectable non-small cell lung cancer

por Wang, Kaichao, Shen, Shaohui, Dong, Liyuan, Fang, Qinmo, Hou, Xinlei, Shi, Xueliang
Publicado 2023